NCT03206073 2023-10-24A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal CancerNational Institutes of Health Clinical Center (CC)Phase 1/2 Completed34 enrolled 18 charts